Table 1.
Clinical features of the enrolled patients in training set and validation set
| Clinical factors | Traning set | Internal validation set | External validation set | ||||||
|---|---|---|---|---|---|---|---|---|---|
| LCLNM | Non_LCLNM | P-value | LCLNM | Non_LCLNM | P-value | LCLNM | Non_LCLNM | P-value | |
| (N = 202) | (N = 70) | (N = 87) | (N = 30) | (N = 23) | (N = 17) | ||||
| Age | 40.41 ± 11.65 | 45 ± 11.87 | 0.006 | 43 ± 12.03 | 42 ± 11.43 | 0.685 | 44.65 ± 14.28 | 38 ± 12.85 | 0.131 |
| Gender | 0.823 | 0.912 | 0.216 | ||||||
| Male | 53 (26.24%) | 20 (28.57%) | 29 (33.33%) | 9 (30.00%) | 5 (21.74%) | 1 (5.88%) | |||
| Female | 149 (73.76%) | 50 (71.43%) | 58 (66.67%) | 21 (70.00%) | 18 (78.26%) | 16 (94.12%) | |||
| Course | 7.61 ± 16.17 | 7.89 ± 10.87 | 0.871 | 10.24 ± 27.8 | 4.41 ± 8.48 | 0.086 | 15.6 ± 34.11 | 6.86 ± 11.34 | 0.261 |
| BMI | 23.71 ± 3.6 | 24.82 ± 3.87 | 0.038 | 24.55 ± 4.38 | 25.14 ± 4.07 | 0.501 | 24.6 ± 4.09 | 22.44 ± 2.21 | 0.039 |
| Tumor size | 1.78 ± 1.07 | 1.65 ± 2.79 | 0.705 | 1.89 ± 1.14 | 1.48 ± 1.62 | 0.206 | 1.44 ± 1.32 | 1.36 ± 0.77 | 0.824 |
| Tumor location | 0.016 | <0.001 | 0.014 | ||||||
| Isthmus | 4 (1.98%) | 5 (7.14%) | 1 (1.15%) | 1 (3.33%) | 2 (8.70%) | 0 (0.00%) | |||
| Upper | 83 (41.09%) | 20 (28.57%) | 36 (41.38%) | 3 (10.00%) | 11 (47.83%) | 2 (11.76%) | |||
| Middle | 77 (38.12%) | 23 (32.86%) | 38 (43.68%) | 12 (40.00%) | 5 (21.74%) | 4 (23.53%) | |||
| Lower | 38 (18.81%) | 22 (31.43%) | 12 (13.79%) | 14 (46.67%) | 5 (21.74%) | 11 (64.71%) | |||
| Capsule invasion | 0.019 | 0.626 | 0.12 | ||||||
| Negative | 165 (81.68%) | 66 (94.29%) | 70 (80.46%) | 26 (86.67%) | 8 (34.78%) | 11 (64.71%) | |||
| Positive | 37 (18.32%) | 4 (5.71%) | 17 (19.54%) | 4 (13.33%) | 15 (65.22%) | 6 (35.29%) | |||
| Hashimoto thyroiditis | 0.501 | 0.372 | 0.712 | ||||||
| Negative | 135 (66.83%) | 43 (61.43%) | 54 (62.07%) | 22 (73.33%) | 16 (69.57%) | 10 (58.82%) | |||
| Positive | 67 (33.17%) | 27 (38.57%) | 33 (37.93%) | 8 (26.67%) | 7 (30.43%) | 7 (41.18%) | |||
| Thyroid nodules | 0.491 | 1 | 0.675 | ||||||
| Negative | 160 (79.21%) | 52 (74.29%) | 68 (78.16%) | 24 (80.00%) | 15 (65.22%) | 13 (76.47%) | |||
| Positive | 42 (20.79%) | 18 (25.71%) | 19 (21.84%) | 6 (20.00%) | 8 (34.78%) | 4 (23.53%) | |||
| T3 | 2.16 ± 1.54 | 2.01 ± 0.43 | 0.217 | 2.06 ± 0.61 | 2.05 ± 0.48 | 0.942 | 1.76 ± 0.24 | 2.06 ± 0.48 | 0.028 |
| T4 | 109.35 ± 20.24 | 108.35 ± 20.85 | 0.729 | 108.67 ± 27.95 | 106.5 ± 29.82 | 0.729 | 92.83 ± 33.98 | 95.14 ± 26.95 | 0.812 |
| FT3 | 5.53 ± 3.46 | 5.06 ± 1.01 | 0.081 | 5.11 ± 2.15 | 5.06 ± 1.02 | 0.876 | 5.02 ± 0.57 | 5.07 ± 0.83 | 0.862 |
| FT4 | 17.14 ± 2.39 | 16.97 ± 2.52 | 0.615 | 17.07 ± 4.79 | 17.24 ± 3.33 | 0.832 | 17.33 ± 3.1 | 16.05 ± 2.41 | 0.15 |
| TSH | 2.32 ± 1.72 | 2.26 ± 1.29 | 0.767 | 2.4 ± 2.04 | 2.55 ± 1.79 | 0.718 | 6.24 ± 14.25 | 2.6 ± 1.22 | 0.235 |
| TG | 52.68 ± 105.87 | 34.2 ± 68.53 | 0.097 | 37.41 ± 92.35 | 26.4 ± 39.14 | 0.369 | 105.16 ± 168.08 | 23.77 ± 29.74 | 0.032 |
| TGAb | 211.82 ± 544.87 | 767.88 ± 5649.18 | 0.414 | 423.21 ± 2731.76 | 59.37 ± 86.73 | 0.218 | 181.91 ± 728.8 | 162.13 ± 288.13 | 0.907 |
| TMAb | 10.49 ± 10.37 | 9.79 ± 10.27 | 0.626 | 10.25 ± 9.78 | 8.57 ± 7.47 | 0.331 | 10.49 ± 12.93 | 9.36 ± 8.02 | 0.736 |
| TPOAb | 49.16 ± 91.9 | 51.27 ± 76.95 | 0.851 | 42.69 ± 73.41 | 49.83 ± 59.36 | 0.596 | 50.93 ± 106.73 | 97.98 ± 191.86 | 0.371 |
| CCLNM | <0.001 | <0.001 | 0.03 | ||||||
| Negative | 20 (9.90%) | 32 (45.71%) | 11 (12.64%) | 19 (63.33%) | 3 (13.04%) | 8 (47.06%) | |||
| Positive | 182 (90.10%) | 38 (54.29%) | 76 (87.36%) | 11 (36.67%) | 20 (86.96%) | 9 (52.94%) | |||
TSH, thyroid stimulating hormone.